News & Updates
Filter by Specialty:
Poststroke statin treatment confers survival benefits for cancer patients
Statin treatment following ischaemic stroke appears to extend its benefits to improved survival in patients who also have had cancer, a study has found.
Poststroke statin treatment confers survival benefits for cancer patients
16 Sep 2022
Proximal gastrectomy OK for proximal advanced gastric cancer
For patients with proximal advanced gastric cancer (AGC), proximal gastrectomy (PG) appears to be a reasonable treatment option, particularly for those with small tumours, a recent study has found.
Proximal gastrectomy OK for proximal advanced gastric cancer
16 Sep 2022
Maximal androgen blockade the prime prostate cancer treatment option in older patients
Among prostate cancer patients aged ≥75 years, maximal androgen blockage (MAB) appears to be the most common treatment option, reports a new South Korea study. Meanwhile, the combination of leuprolide and bicalutamide is the most common MAB regimen.
Maximal androgen blockade the prime prostate cancer treatment option in older patients
16 Sep 2022
First-line rucaparib boosts PFS in ovarian cancer regardless of HRD status
First-line rucaparib maintenance therapy extends progression-free survival (PFS) in patients with ovarian, fallopian tube, or primary peritoneal cancer, according to results of the phase III ATHENA-MONO trial presented at the ESMO Gynaecological Cancers Conference 2022.
First-line rucaparib boosts PFS in ovarian cancer regardless of HRD status
15 Sep 2022
Any upside to frontline mFOLFOXIRI-panitumumab in mCRC?
In patients with unresectable RAS and BRAF wildtype metastatic colorectal cancer (mCRC), a modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN*) treatment strategy in the first-line setting did not improve objective response rate (ORR) compared with FOLFOX plus panitumumab (mFOLFOX6/PAN**), results of the phase III TRIPLETE study showed.